SlateStone Wealth LLC decreased its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 70.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,300 shares of the financial services provider’s stock after selling 15,241 shares during the quarter. SlateStone Wealth LLC’s holdings in iShares Biotechnology ETF were worth $833,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF in the 3rd quarter worth $29,000. HHM Wealth Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 200.0% in the 4th quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Bradley & Co. Private Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter worth about $32,000. Newbridge Financial Services Group Inc. purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter worth about $33,000. Finally, Hager Investment Management Services LLC purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter worth about $34,000. Institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
Shares of NASDAQ:IBB opened at $134.19 on Monday. The company’s 50-day moving average is $136.25 and its 200 day moving average is $139.76. The company has a market capitalization of $6.34 billion, a P/E ratio of 24.52 and a beta of 0.84. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- When to Sell a Stock for Profit or Loss
- How to Build the Ultimate Everything ETF Portfolio
- How to Invest in Small Cap Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Election Stocks: How Elections Affect the Stock Market
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
